Manufacturer of Controlled Substances; Notice of Registration, 48980-48981 [05-16565]

Download as PDF 48980 Federal Register / Vol. 70, No. 161 / Monday, August 22, 2005 / Notices made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on October 25, 2004, Navinta LLC, 1499 Lower Ferry Road, Ewing, New Jersey 08616–1414, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic class of controlled substances listed in Schedule II: Drug a bulk manufacturer of the basic class of controlled substances listed in Schedule II. Drug Cocaine (9041) ......................... Benzoylecgonine (9180) ........... Schedule Lysergic Acid Diethylamide (7315) .................................... Tetrahydrocannabinol (7370) ... Alphamethadol (9605) .............. Phencyclidine (7471) ................ Benzoylecgonine (9180) ........... Methadone (9250) .................... Morphine (9300) ....................... I I I II II II II The company plans to manufacture small quantities of the listed controlled Fentanyl (9801) ........................ II substances for use in diagnostic Sufentanil (9740) ...................... II products. No comments or objections have been received. DEA has considered the The company plans to bulk factors in 21 U.S.C. 823(a) and manufacture the controlled substances for product development of generic and determined that the registration of Roche Diagnostics Operations Inc. to brand pharmaceutical products. Any other such applicant and any manufacture the listed basic classes of person who is presently registered with controlled substances is consistent with DEA to manufacture such a substance the public interest at this time. DEA has may file comments or objections to the investigated Roche Diagnostics issuance of the proposed registration Operations Inc. to ensure that the pursuant to 21 CFR 1301.33(a). company’s registration is consistent Any such written comments or with the public interest. The objections being sent via regular mail investigation has included inspection may be addressed, in quintuplicate, to and testing of the company’s physical the Deputy Assistant Administrator, security systems, verification of the Office of Diversion Control, Drug company’s compliance with state and Enforcement Administration, local laws, and a review of the Washington, DC 20537, Attention: DEA company’s background and history. Federal Register Representative, Liaison Therefore, pursuant to 21 U.S.C. 823, and Policy Section (ODL); or any being and in accordance with 21 CFR 1301.33, sent via express mail should be sent to the above named company is granted DEA Headquarters, Attention: DEA registration as a bulk manufacturer of Federal Register Representative/ODL, the basic classes of controlled 2401 Jefferson-Davis Highway, substances listed. Alexandria, Virginia 22301; and must be Dated: August 15, 2005. filed no later than October 21, 2005. Drug Schedule Dated: August 15, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–16567 Filed 8–19–05; 8:45 am] William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–16568 Filed 8–19–05; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration Manufacturer of Controlled Substances; Notice of Registration By notice dated April 25, 2005, and published in the Federal Register on May 2, 2005, (70 FR 22704), Roche Diagnostics Operations Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, VerDate jul<14>2003 16:09 Aug 19, 2005 Jkt 205001 By notice dated March 29, 2005, and published in the Federal Register on April 5 2005 (70 FR 17263), Stepan Company, Natural Products Dept., 100 W. Hunter Avenue, Maywood, New Jersey 07607, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 Schedule II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Stepan Company to manufacture the listed basic class of controlled substances is consistent with the public interest at this time. DEA has investigated Stepan Company to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substances listed. Dated: August 15, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–16566 Filed 8–19–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By notice dated March 29, 2005, and published in the Federal Register on April 6, 2005, (70 FR 17474–17475), Varian, Inc., Lake Forest, 25200 Commercentre Drive, Lake Forest, California 92630–8810, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic class of controlled substances listed in Schedule II: Drug Phencyclidine (7471) ................ 1-Piperidinocyclohexanecarbonitrile (8603) ................. Benzoylecgonine (9180) ........... E:\FR\FM\22AUN1.SGM 22AUN1 Schedule II II II Federal Register / Vol. 70, No. 161 / Monday, August 22, 2005 / Notices The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Varian, Inc. to manufacture the listed basic class of controlled substances is consistent with the public interest at this time. DEA has investigated Varian, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substances listed. Dated: August 15, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–16565 Filed 8–19–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Office of Justice Programs Agency Information Collection Activities: Proposed Collection; Comments Requested 60-day notice of information collection under review: 2005 Census of Publicly Funded Forensic Crime Laboratories. ACTION: The Department of Justice (DOJ), Office of Justice Programs (OJP), Bureau of Justice Statistics (BJS), has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for ‘‘sixty days’’ until October 21, 2005. This process is conducted in accordance with 5 CFR 1320.10. If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, VerDate jul<14>2003 16:09 Aug 19, 2005 Jkt 205001 please contact Matthew Hickman, Bureau of Justice Statistics, 810 Seventh St., NW., Washington, DC 20531. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of this information collection: (1) Type of Information Collection: Revision of a currently approved collection. (2) Title of the Form/Collection: 2005 Census of Publicly Funded Forensic Crime Laboratories. (3) Agency Form Number, if Any, and the Applicable Component of the Department of Justice Sponsoring the Collection: Form Number: The form number is CFCL–1, Bureau of Justice Statistics, Office of Justice Programs, Department of Justice. (4) Affected Public Who Will be Asked or Required to Respond, as Well as a Brief Abstract: Primary: State, Local, or Tribal Government. Other: Federal Government. This information collection is a census of public crime laboratories that perform forensic analyses on criminal evidence. The information will provide statistics on laboratories’ capacity to analyze forensic crime evidence, the number, types, and sources of evidence received per year, and the number, types, and costs of analyses completed. (5) An Estimate of the Total Number of Respondents and the Amount of Time Estimated for an Average Respondent to Respond: It is estimated that 375 respondents will complete a three hour form. (6) An Estimate of the Total Public Burden (in Hours) Associated With the PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 48981 Collection: There are an estimated 1,125 total annual burden hours associated with this collection. If additional information is required contact: Brenda E. Dyer, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street NW., Washington, DC 20530. Dated: August 17, 2005. Brenda E. Dyer, Department Clearance Officer, Department of Justice. [FR Doc. 05–16547 Filed 8–19–05; 8:45 am] BILLING CODE 4410–18–P DEPARTMENT OF JUSTICE Office of Justice Programs Agency Information Collection Activities: Proposed Collection; Comment Requested 60-day notice of information collection under review: 2006 Census of Adult Parole Supervising Agencies. ACTION: The Department of Justice (DOJ), Office of Justice Programs, has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for ‘‘sixty days’’ until October 21, 2005. This process is in accordance with 5 CFR 1320.10. If you have comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Lawrence Greenfeld, Director, Bureau of Justice Statistics, 810 Seventh St. NW., Washington, DC 20531. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information. Your comments should address one or more of the following four points: —Evaluate whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, E:\FR\FM\22AUN1.SGM 22AUN1

Agencies

[Federal Register Volume 70, Number 161 (Monday, August 22, 2005)]
[Notices]
[Pages 48980-48981]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-16565]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By notice dated March 29, 2005, and published in the Federal 
Register on April 6, 2005, (70 FR 17474-17475), Varian, Inc., Lake 
Forest, 25200 Commercentre Drive, Lake Forest, California 92630-8810, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic class of 
controlled substances listed in Schedule II:

------------------------------------------------------------------------
                            Drug                               Schedule
------------------------------------------------------------------------
Phencyclidine (7471).......................................           II
1-Piperidinocyclohexane-carbonitrile (8603)................           II
Benzoylecgonine (9180).....................................           II
------------------------------------------------------------------------


[[Page 48981]]

    The company plans to manufacture small quantities of the listed 
controlled substances for use in diagnostic products.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Varian, Inc. to manufacture the listed basic class of controlled 
substances is consistent with the public interest at this time. DEA has 
investigated Varian, Inc. to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic class of controlled substances listed.

    Dated: August 15, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-16565 Filed 8-19-05; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.